Johnson & Johnson (JNJ) stock analysis

Healthcare · Drug Manufacturers - General

From the 10-K filed 2026-02-11

Business type: Franchise

How it makes money

It generates $94.2 billion in sales by distributing specialized therapeutics like STELARA and DARZALEX to a global network of wholesalers and hospitals.

The business operates via two segments: Innovative Medicine and MedTech. Innovative Medicine provides the majority of revenue through high-value therapeutic areas such as oncology and immunology, where medicines are distributed for prescription use.

In 2025, total sales grew 6.0% to $94.2 billion. While volume increased 8.4%, the company faced a 3.1% pricing decline, highlighting a reliance on unit growth to offset regulatory and competitive price pressures.

What protects it: the moat

It protects its earnings through patent exclusivity for innovative medicines and the professional reputation of its surgical, orthopaedic, and cardiovascular technology portfolios.

For the Innovative Medicine segment, intellectual property rights prevent rivals from introducing lower-cost generic or biosimilar versions of its treatments. In MedTech, competitiveness is driven by technical innovation and the integration of its tools into hospital workflows, where brand reputation is paramount for physicians and nurses.

What growth costs

It reinvests $14.7 billion annually into research and development to refresh a portfolio where 25% of sales come from products launched within five years.

Maintaining revenue scale requires constant innovation due to the lifecycle of medical patents. The company spent $14.7 billion on R&D in 2025 to sustain a pipeline that successfully replaced one quarter of its total volume with products released since 2020.

Growth is also supplemented by acquisitions, with recent additions like Shockwave and the licensing of CAPLYTA contributing 1.1% to the 2025 sales growth rate.

What could damage it

Loss of patent exclusivity triggers a permanent impairment of earnings as generic and biosimilar competitors gain regulatory approval to displace its high-margin medicines.

The primary threat to the company’s earnings power is the 'patent cliff' in the Innovative Medicine segment. Once a patent expires, the entry of generic or biosimilar products typically results in an immediate and substantial reduction in sales volume and pricing power for that specific therapy.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

More on JNJ

Other companies in Drug Manufacturers - General